Cargando…
Antiseizure medication treatment pathways for US Medicare beneficiaries with newly treated epilepsy
OBJECTIVE: This study was undertaken to characterize antiseizure medication (ASM) treatment pathways in Medicare beneficiaries with newly treated epilepsy. METHODS: This was a retrospective cohort study using Medicare claims. Medicare is the United States' federal health insurance program for p...
Autores principales: | Terman, Samuel W., Youngerman, Brett E., Choi, Hyunmi, Burke, James F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314094/ https://www.ncbi.nlm.nih.gov/pubmed/35294775 http://dx.doi.org/10.1111/epi.17226 |
Ejemplares similares
-
Incidence of and predictors for antiseizure medication gaps in Medicare beneficiaries with epilepsy: a retrospective cohort study
por: Terman, Samuel W., et al.
Publicado: (2022) -
Predictors of referral for long‐term EEG monitoring for Medicare beneficiaries with drug‐resistant epilepsy
por: Hill, Chloe E., et al.
Publicado: (2023) -
Response to subsequent antiseizure medications after first antiseizure medication failure in newly diagnosed epilepsy
por: Hersi, Hire, et al.
Publicado: (2022) -
Effect of clinical features on antiseizure medication doses in patients with newly diagnosed epilepsy
por: Hersi, Hire, et al.
Publicado: (2023) -
Frequency of and factors associated with antiseizure medication discontinuation discussions and decisions in patients with epilepsy: A multicenter retrospective chart review
por: Terman, Samuel W., et al.
Publicado: (2023)